Rapid regression of extensive retinovitreal neovascularization secondary to branch retinal vein occlusion after a single intravitreal injection of bevacizumab

被引：15

作者：

Ahmadieh H. ^{[1
]}

Moradian S. ^{[1
]}

Malihi M. ^{[1
]}

机构：

[1] Department of Ophthalmology, Ophthalmic Research Center, Shaheed Beheshti Medical University, Tehran 16666

来源：

International Ophthalmology | 2005年 / 26卷 / 4-5期

关键词：

Avastin; Bevacizumab; Branch retinal vein occlusion; Retinovitreal neovascularization;

D O I：

10.1007/s10792-007-9036-y

中图分类号：

学科分类号：

摘要：

Purpose: To report the rapid regression of extensive retinovitreal neovascularization following the administration of a single dose of intravitreal bevacizumab. Methods: A 60-year-old woman presented with recurrent vitreous hemorrhage originating from active retinovitreal neovascularization secondary to branch retinal vein occlusion. The neovascular tissue remained active despite multiple sessions of laser therapy. Intravitreal injection of 1.25 mg bevacizumab was performed. Results: Rapid regression of the retinovitreal neovascularization, a marked reduction in retinal vein engorgement, and visual improvement was observed 1 week after the intervention. Conclusion: Intravitreal bevacizumab can result in the rapid and dramatic regression of retinovitreal neovascularization refractory to previous laser photocoagulation. © Springer Science+Business Media, Inc. 2007.

引用

页码：191 / 193

页数：2

共 5 条

[1]

Ferrara N., Vascular endothelial growth factor: Basic science in clinical progress, Endocrinol Rev, 25, pp. 581-611, (2004)

[2]

Adamis P.A., Shima D.T., The role of vascular endothelial growth factor in ocular health and disease, Retina, 25, pp. 111-118, (2005)

[3]

Changes in retinal neovascularization following pegaptanib (Macugen) therapy in diabetic individuals, Ophthalmology, 113, pp. 23-28, (2006)

[4]

Rabena M., Pieramici D.J., Castellarin A.A., Nasir M.A., Giust M.J., Avery R.L., Intravitreal bevacizumab for retinal vein occlusion, Abstr ARVO 2006 Annu Meet, (2006)

[5]

Avery R.L., Pieramici D.J., Rabena M.D., Castellarin A.A., Nasir M.A., Giust M.J., Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration, Ophthalmology, 113, pp. 363-372, (2006)

← 1 →